The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

Autor: Zuoshun Zhang, Kristian Reich, Melinda Gooderham, K. Shah, Lawrence Green, J. Soung, Robert M. Day, Anthony Bewley, Vincent Piguet, Joana Carla Soares Gonçalves, I. Khanskaya

Publikováno v: Journal of the European Academy of Dermatology and Venereology

Background Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis. Objective Evaluate efficacy and safety of apremilast vs. placebo in biologic-naive patients with mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64123e37b55fd978c407e3075bea5098
https://doi.org/10.1111/jdv.14015

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Autor: Christopher E.M. Griffiths, Richard G. Langley, Kenneth B. Gordon, R. Stevens, Leon H Kircik, Kristian Reich, Kim A. Papp, Chia Chi Hu, Craig L. Leonardi, Robert M. Day, Sergio Chimenti, Neil J. Korman

Publikováno v: Journal of the American Academy of Dermatology. 73(1):37-49

BackgroundApremilast works intracellularly to regulate inflammatory mediators.ObjectiveESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.MethodsThis phase III, multicenter, double-blind, pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b1638cfd72db41712e4b274fb27a95

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Autor: Rongdean Chen, Pascal Joly, Robert M. Day, Jeffrey J. Crowley, Diamant Thaçi, Ketty Peris, K. Shah, Kim A. Papp, Joana Carla Soares Gonçalves, Jennifer Clay Cather, Carlos Ferrándiz

Publikováno v: Journal of The American Academy of Dermatology
Journal of The American Academy of Dermatology, Elsevier, 2017, 77 (2), pp.310-317.e1. ⟨10.1016/j.jaad.2017.01.052⟩
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of The American Academy of Dermatology, 2017, 77 (2), pp.310-317.e1. ⟨10.1016/j.jaad.2017.01.052⟩

BACKGROUND: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: Assess long-term safety of oral apremilast in psoriasis patients. METHODS: Safety fin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f75b63ccb41cd49cce73611bb2577d
https://doi.org/10.1016/j.jaad.2017.01.052

The Business of Sustainable Forestry: Meshing Operations with Strategic Purpose

Autor: Matthew B. Arnold, Robert M. Day, Stuart L. Hart

Publikováno v: Interfaces. 30:234-250

We developed a new framework for defining sustainable forest management (SFM) based on the literature on environmental strategy and a field study of forest-product companies. We applied the framework to 21 forest-industry business cases and found tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6c4f90ae692016f94b5b6611474a2dbb
https://doi.org/10.1287/inte.30.3.234.11652

L’apremilast dans le psoriasis en plaques modéré à sévère : résultats à 32 semaines sur l’atteinte unguéale, palmo-plantaire et du cuir chevelu (ESTEEM 2)

Autor: M. Sebastian, Carlos Ferrándiz, Jeffrey J. Crowley, Giampiero Girolomoni, Robert M. Day, J. Cather, M. Beylot-Barry, H. ChiaChi, Melinda Gooderham

Publikováno v: Annales de Dermatologie et de Vénéréologie. 142:S670-S671

Introduction L’apremilast (APR), un inhibiteur intracellulaire oral de la phosphodiesterase 4, regule les mediateurs inflammatoires impliques dans le psoriasis. Patients et methodes Des patients atteints de psoriasis en plaques modere a severe –

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d2bc42782e58d9cdd2f5395d4c0cd1e
https://doi.org/10.1016/j.annder.2015.10.520